MCL Clinical Trials
1230 trials from ClinicalTrials.gov. Recruiting trials shown first.
Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant
ACTIVE NOT RECRUITINGNCT03622788·PHASE1 / PHASE2·M.D. Anderson Cancer Center·16 enrolled
Anti-Thymocyte GlobulinCyclophosphamideCytokine-treated Veto CellsFludarabinePeripheral Blood Stem Cell Transplantation+1 more
Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
ACTIVE NOT RECRUITINGNCT03710772·PHASE2·M.D. Anderson Cancer Center·51 enrolled
CyclophosphamideCytarabineDexamethasoneDoxorubicin HydrochlorideIbrutinib+4 more
Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma
ACTIVE NOT RECRUITINGNCT03872180·PHASE2·Emory University·23 enrolled
BendamustineObinutuzumabVenetoclax
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
ACTIVE NOT RECRUITINGNCT03674411·PHASE2·Masonic Cancer Center, University of Minnesota·22 enrolled
Fludarabine (FLU)Cyclophosphamide (CY)Total Body Irradiation (TBI)Tacrolimus (Tac)Mycophenolate Mofetil (MMF)+4 more
Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma
ACTIVE NOT RECRUITINGNCT03478514·PHASE2·Alliance Foundation Trials, LLC.·39 enrolled
PalbociclibIbrutinib
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma
ACTIVE NOT RECRUITINGNCT03479268·PHASE1·City of Hope Medical Center·18 enrolled
IbrutinibLaboratory Biomarker AnalysisPevonedistatPharmacokinetic StudyPharmacological Study
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas
ACTIVE NOT RECRUITINGNCT03277729·PHASE1 / PHASE2·Fred Hutchinson Cancer Center·53 enrolled
Chimeric Antigen Receptor T-Cell TherapyCyclophosphamideLaboratory Biomarker AnalysisLeukapheresisFludarabine Phosphate
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
ACTIVE NOT RECRUITINGNCT03267433·PHASE3·ECOG-ACRIN Cancer Research Group·689 enrolled
Autologous Hematopoietic Stem Cell TransplantationBiospecimen CollectionBone Marrow AspirateBone Marrow BiopsyComputed Tomography+3 more
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
ACTIVE NOT RECRUITINGNCT02952508·PHASE2·Cellectar Biosciences, Inc.·120 enrolled
Iopofosine I 131 single doseIopofosine I 131 multiple doseIopofosine I 131 fractionated dose
Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients With Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL)
ACTIVE NOT RECRUITINGNCT03153202·PHASE1 / PHASE2·Joshua Brody·23 enrolled
IbrutinibPembrolizumab
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)
ACTIVE NOT RECRUITINGNCT03162536·PHASE1 / PHASE2·ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)·190 enrolled
Nemtabrutinib
Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma
ACTIVE NOT RECRUITINGNCT03147885·PHASE1 / PHASE2·Barbara Ann Karmanos Cancer Institute·43 enrolled
Selinexor
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
ACTIVE NOT RECRUITINGNCT02972840·PHASE3·Acerta Pharma BV·635 enrolled
AcalabrutinibBendamustineRituximabPlacebo
Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
ACTIVE NOT RECRUITINGNCT03015896·PHASE1 / PHASE2·David Bond, MD·36 enrolled
Laboratory Biomarker AnalysisLenalidomideNivolumab
Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant
ACTIVE NOT RECRUITINGNCT02797470·PHASE1 / PHASE2·AIDS Malignancy Consortium·11 enrolled
Autologous Hematopoietic Stem Cell TransplantationCarmustineCytarabineEtoposideLaboratory Biomarker Analysis+3 more
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
ACTIVE NOT RECRUITINGNCT02339922·PHASE2·University of Washington·33 enrolled
Ixazomib CitrateLaboratory Biomarker AnalysisRituximab
Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of MCL
ACTIVE NOT RECRUITINGNCT02682641·PHASE2·Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea·50 enrolled
IBRUTINIBRituximab
A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL
ACTIVE NOT RECRUITINGNCT02717624·PHASE1·Acerta Pharma BV·72 enrolled
Acalabrutinib in combination with BRAcalabrutinib in combination with VR
Ultra Low Dose Orbital Radiation Therapy in Treating Patients With Stage I-IV Indolent B-cell Lymphoma or Mantle Cell Lymphoma
ACTIVE NOT RECRUITINGNCT02494700·PHASE2·M.D. Anderson Cancer Center·50 enrolled
External Beam Radiation TherapyOrbital Radiation
Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma
ACTIVE NOT RECRUITINGNCT02446236·PHASE1·Hackensack Meridian Health·27 enrolled
LenalidomideIbrutinibRituximab
Ibrutinib, Rituximab, and Consolidation Chemotherapy in Treating Young Patients With Newly Diagnosed Mantle Cell Lymphoma
ACTIVE NOT RECRUITINGNCT02427620·PHASE2·M.D. Anderson Cancer Center·131 enrolled
CyclophosphamideCytarabineDexamethasoneDoxorubicinDoxorubicin Hydrochloride+6 more
An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma
ACTIVE NOT RECRUITINGNCT02213926·PHASE2·Acerta Pharma BV·124 enrolled
ACP-196 (acalabrutinib)
Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia
ACTIVE NOT RECRUITINGNCT02153580·PHASE1·City of Hope Medical Center·37 enrolled
Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytesBendamustine HydrochlorideCyclophosphamideEtoposideFludarabine Phosphate
Ibrutinib and Palbociclib in Treating Patients With Previously Treated Mantle Cell Lymphoma
ACTIVE NOT RECRUITINGNCT02159755·PHASE1·National Cancer Institute (NCI)·28 enrolled
IbrutinibLaboratory Biomarker AnalysisPalbociclibPharmacological Study
Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma
ACTIVE NOT RECRUITINGNCT02051257·PHASE1·City of Hope Medical Center·51 enrolled
Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cellsAutologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytesLaboratory Biomarker Analysis
Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma
ACTIVE NOT RECRUITINGNCT01479842·PHASE1·Kami Maddocks, MD·48 enrolled
BTK inhibitor PCI-32765rituximabbendamustine hydrochloridepharmacogenomic studiespharmacological study+1 more
Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma
ACTIVE NOT RECRUITINGNCT01815749·PHASE1·City of Hope Medical Center·30 enrolled
autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cellsautologous hematopoietic stem cell transplantationlaboratory biomarker analysis
Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
ACTIVE NOT RECRUITINGNCT01955499·PHASE1·National Cancer Institute (NCI)·39 enrolled
Biospecimen CollectionBone Marrow AspirationBone Marrow BiopsyComputed TomographyIbrutinib+3 more
Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma
ACTIVE NOT RECRUITINGNCT01880567·PHASE2·M.D. Anderson Cancer Center·113 enrolled
IbrutinibLaboratory Biomarker AnalysisRituximab
Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma
ACTIVE NOT RECRUITINGNCT01695941·PHASE1·National Cancer Institute (NCI)·24 enrolled
AlisertibBortezomibLaboratory Biomarker AnalysisRituximab